CMS Granted PearlMatrix New Technology Payment Status

The decision provides supplemental Medicare reimbursement for hospitals using the advanced bone graft product.

Updated on Oct. 2, 2026 in Healthcare

Isometric editorial illustration of a porous bone-scaffold structure on a clean surface, representing advanced spinal fusion technology. — The Centers for Medicare and Medicaid Services granted New Technology Add-on Payment status to the PearlMatrix peptide-enhanced bone graft for spinal fusion. AI Illustration. Upload story photo >

Live Poll

Should Medicare provide extra payments to hospitals for adopting expensive new medical technologies?

The Centers for Medicare and Medicaid Services (CMS) has officially granted New Technology Add-on Payment (NTAP) status to the PearlMatrix P-15 Peptide Enhanced Bone Graft. This designation allows hospitals to receive supplemental reimbursement when using the product for spinal fusion procedures on Medicare beneficiaries.

Why it matters

CMS awards NTAP status to novel medical technologies that demonstrate significant clinical improvements over existing options. This designation aims to reduce financial barriers for healthcare facilities, thereby increasing patient access to advanced spinal care.

The NTAP program provides up to 65% reimbursement of the additional cost for the technology, which is used for one-level lumbar spine fusion. The pivotal study for the product reported that over 60% of participating patients were categorized as high-risk.

The players

Centers for Medicare and Medicaid Services

This federal agency oversees the Medicare program and manages the administrative processes for healthcare reimbursement in the United States.

Cerapedics

Headquartered in Westminster, Colorado, this company specializes in the development of orthopedic and spinal bone graft technologies.

The details

PearlMatrix, a Class III drug-device combination, uses a 15-amino-acid peptide to activate osteogenic cells and accelerate bone formation on a calcium phosphate scaffold. The device is specifically indicated for use with interbody fusion hardware and internal fixation systems in patients with degenerative disc disease.

October 1, 2026: The NTAP status for PearlMatrix became effective.
6 months: The timeframe during which fusion rates were measured in the pivotal study.
12 months: A designated follow-up period for patient fusion rates.
24 months: A designated follow-up period for patient fusion rates.

Market Landscape

This approval follows the established framework of the NTAP program, which aims to offset the high costs of innovative medical technologies. By lowering adoption costs for hospitals, this decision strengthens the competitive position of Cerapedics in the annual 4 million procedure market for spine and orthopedic care.

Patients suffering from degenerative disc disease may find that more hospitals are now equipped to offer PearlMatrix due to the reduced financial burden on providers. This policy change could accelerate the broader availability of this bone graft technology within the U.S. healthcare system.

The takeaway

The granting of NTAP status signifies a major regulatory step that validates the clinical performance of the P-15 peptide technology. Patients should consult with their spinal surgeons to determine if new, reimbursed technologies like PearlMatrix are appropriate for their specific degenerative conditions.